Farmacología del amlodipino

dialnet-ar-18-ART0001527304

dialnet

Dialnet

Dialnet AR

RECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 374-380

Spanish

Farmacología
Grupos
Arterial
Angina
Amlodipine
Pharmacology
Groups
Arterial
Angina
Amlodipino

Farmacología
Grupos
Arterial
Angina
Amlodipine
Pharmacology
Groups
Arterial
Angina
Amlodipino
Chan Macías, Shuyin Bernarda
Tapia Toral, Mauro Miguel
Vargas Macías, Carlos Andrés
Guaigua López, Silvia Marcela
Farmacología del amlodipino

Amlodipine is a calcium antagonist, of the dihydropyridine family, and its main function is to inhibit the entry of calcium ions through the cell membranes of cardiac and vascular smooth muscle. The methodology used for this research work is framed within a bibliographic review of documentary type, since we are going to deal with issues raised at a theoretical level such as Pharmacology of amlodipine. The technique for data collection is made up of electronic materials, the latter such as Google Scholar, PubMed, among others, relying on the use of descriptors in health sciences or MESH terminology. The information obtained here will be reviewed for further analysis. Amlodipine is a calcium antagonist with extensive clinical advantages and pharmacokinetic properties, which is classified within the group of dihydropyridines, has the particularity of delaying Cmax, which generates few adverse reactions because vasodilation does not occur as fast as other drugs from the same group. Its elimination within the body has a long half-life of approximately 40 hours and this is due to its volume of distribution capacity and its slow hepatic clearance, which allows a single daily administration, achieving greater therapeutic compliance for the patient. Apart from what has been described above, it can be combined with other antihypertensive drugs, enhancing the hypotensive effect of diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACEI) and alpha-blockers.

Article

Chan Macías, Shuyin Bernarda
Tapia Toral, Mauro Miguel
Vargas Macías, Carlos Andrés
Guaigua López, Silvia Marcela

Chan Macías, Shuyin Bernarda
Tapia Toral, Mauro Miguel
Vargas Macías, Carlos Andrés
Guaigua López, Silvia Marcela

Chan Macías, Shuyin Bernarda

Farmacología del amlodipino

Farmacología del amlodipino

Farmacología del amlodipino

Farmacología del amlodipino

Farmacología del amlodipino

farmacología del amlodipino

2022

https://dialnet.unirioja.es/servlet/oaiart?codigo=8410267

1767464022806888448

dialnet-ar-18-ART00015273042023-05-30Farmacología del amlodipinoChan Macías, Shuyin BernardaTapia Toral, Mauro MiguelVargas Macías, Carlos AndrésGuaigua López, Silvia MarcelaFarmacologíaGruposArterialAnginaAmlodipinePharmacologyGroupsArterialAnginaAmlodipinoAmlodipine is a calcium antagonist, of the dihydropyridine family, and its main function is to inhibit the entry of calcium ions through the cell membranes of cardiac and vascular smooth muscle. The methodology used for this research work is framed within a bibliographic review of documentary type, since we are going to deal with issues raised at a theoretical level such as Pharmacology of amlodipine. The technique for data collection is made up of electronic materials, the latter such as Google Scholar, PubMed, among others, relying on the use of descriptors in health sciences or MESH terminology. The information obtained here will be reviewed for further analysis. Amlodipine is a calcium antagonist with extensive clinical advantages and pharmacokinetic properties, which is classified within the group of dihydropyridines, has the particularity of delaying Cmax, which generates few adverse reactions because vasodilation does not occur as fast as other drugs from the same group. Its elimination within the body has a long half-life of approximately 40 hours and this is due to its volume of distribution capacity and its slow hepatic clearance, which allows a single daily administration, achieving greater therapeutic compliance for the patient. Apart from what has been described above, it can be combined with other antihypertensive drugs, enhancing the hypotensive effect of diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACEI) and alpha-blockers.El amlodipino es un antagonista del calcio, de la familia de dihidropiridinas, y su función principal es inhibir la entrada de iones de calcio a través de las membranas celulares de los músculos cardíaco y liso vascular. La metodología utilizada para el presente trabajo de investigación, se enmarcada dentro de una revisión bibliográfica de tipo documental, ya que nos vamos a ocupar de temas planteados a nivel teórico como es Farmacología del amlodipino. La técnica para la recolección de datos está constituida por materiales electrónicos, estos últimos como Google Académico, PubMed, entre otros, apoyándose para ello en el uso de descriptores en ciencias de la salud o terminología MESH. La información aquí obtenida será revisada para su posterior análisis. El amlodipino es un antagonista del calcio con amplias ventajas clínicas y propiedades farmacocinéticas, que está clasificado dentro del grupo de las dihidropiridinas, tiene la particularidad de retrasar el Cmáx, lo que genera pocas reacciones adversas porque no se produce una vasodilatación tan rápida como otros fármacos del mismo grupo. Su eliminación dentro del organismo tiene una larga vida media de aproximadamente 40 horas y esto debido a su capacidad de volumen de distribución y su lento aclaramiento hepático, lo que permite una administración única diaria, logrando un mayor cumplimiento terapéutico para el paciente. Aparte de lo anteriormente descrito puede ser combinado con otros fármacos antihipertensivos, potenciando el efecto hipotensor de diuréticos, betabloqueantes, inhibidores de la enzima de conversión de la angiotensina (IECA) y alfabloqueantes.2022text (article)application/pdfhttps://dialnet.unirioja.es/servlet/oaiart?codigo=8410267(Revista) ISSN 2588-073XRECIMUNDO: Revista Científica de la Investigación y el Conocimiento, ISSN 2588-073X, Vol. 6, Nº. 2, 2022, pags. 374-380spaLICENCIA DE USO: Los documentos a texto completo incluidos en Dialnet son de acceso libre y propiedad de sus autores y/o editores. Por tanto, cualquier acto de reproducción, distribución, comunicación pública y/o transformación total o parcial requiere el consentimiento expreso y escrito de aquéllos. Cualquier enlace al texto completo de estos documentos deberá hacerse a través de la URL oficial de éstos en Dialnet. Más información: https://dialnet.unirioja.es/info/derechosOAI | INTELLECTUAL PROPERTY RIGHTS STATEMENT: Full text documents hosted by Dialnet are protected by copyright and/or related rights. This digital object is accessible without charge, but its use is subject to the licensing conditions set by its authors or editors. Unless expressly stated otherwise in the licensing conditions, you are free to linking, browsing, printing and making a copy for your own personal purposes. All other acts of reproduction and communication to the public are subject to the licensing conditions expressed by editors and authors and require consent from them. Any link to this document should be made using its official URL in Dialnet. More info: https://dialnet.unirioja.es/info/derechosOAI